Expression patterns of nicotinamide phosphoribosyltransferase and nicotinic acid phosphoribosyltransferase in human malignant lymphomas

Nicotinamide Phosphoribosyl Transferase/Pre-B Cell Colony-Enhancing Factor/Visfatin Is Required for Lymphocyte Development and Cellular Resistance to Genotoxic Stress

(2014) A. Rongvaux et al.   JOURNAL OF IMMUNOLOGY

Target enzyme mutations are the molecular basis for resistance towards pharmacological inhibition of nicotinamide phosphoribosyltransferase

(2011) Uffe H Olesen et al.   BMC CANCER

A Preclinical Study on the Rescue of Normal Tissue by Nicotinic Acid in High-Dose Treatment with APO866, a Specific Nicotinamide Phosphoribosyltransferase Inhibitor

(2010) U. H. Olesen et al.   MOLECULAR CANCER THERAPEUTICS

The NAD biosynthesis inhibitor APO866 has potent antitumor activity against hematologic malignancies

(2009) A. Nahimana et al.   BLOOD

Nicotinamide Phosphoribosyltransferase (Nampt): A Link Between NAD Biology, Metabolism, and Diseases

(2009) Shin-ichiro Imai   CURRENT PHARMACEUTICAL DESIGN

Histone deacetylase 1, 2, 6 and acetylated histone H4 in B- and T-cell lymphomas

(2009) Lena Marquard et al.   HISTOPATHOLOGY

The Small Molecule GMX1778 Is a Potent Inhibitor of NAD+ Biosynthesis: Strategy for Enhanced Therapy in Nicotinic Acid Phosphoribosyltransferase 1-Deficient Tumors

(2009) M. Watson et al.   MOLECULAR AND CELLULAR BIOLOGY

Anticancer agent CHS-828 inhibits cellular synthesis of NAD

(2008) Uffe Høgh Olesen et al.   BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS

Evolution and Function of the ADP Ribosyl Cyclase/CD38 Gene Family in Physiology and Pathology

(2008) Fabio Malavasi et al.   PHYSIOLOGICAL REVIEWS

Nampt: linking NAD biology, metabolism and cancer

(2008) Antje Garten et al.   TRENDS IN ENDOCRINOLOGY AND METABOLISM